These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 29157944)

  • 1. Down-regulation of TYK2, CBLB and LMP7 genes expression in relapsing-remitting multiple sclerosis patients treated with interferon-beta.
    Mazdeh M; Moradi N; Khoshroo E; Shayesteh Z; Taheri M; Sayad A; Omrani MD; Hajilooi M; Roshanaei G; Solgi G
    J Neuroimmunol; 2018 Jan; 314():24-29. PubMed ID: 29157944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.
    Khademi M; Wallström E; Andersson M; Piehl F; Di Marco R; Olsson T
    J Neuroimmunol; 2000 Mar; 103(2):202-10. PubMed ID: 10696916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aligned Expression of IFI16 and STING Genes in RRMS Patients' Blood.
    Helbi S; Ravanbakhsh B; Karimi M; Kooti W; Jivad N
    Endocr Metab Immune Disord Drug Targets; 2020; 20(6):878-886. PubMed ID: 31362682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: a longitudinal 1-year study.
    Aristimuño C; de Andrés C; Bartolomé M; de las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    Clin Immunol; 2010 Feb; 134(2):148-57. PubMed ID: 19900844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders.
    Carrieri PB; Ladogana P; Di Spigna G; de Leva MF; Petracca M; Montella S; Buonavolontà L; Florio C; Postiglione L
    Immunopharmacol Immunotoxicol; 2008; 30(4):1-9. PubMed ID: 18686100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis.
    Petzold A; Brassat D; Mas P; Rejdak K; Keir G; Giovannoni G; Thompson EJ; Clanet M
    Mult Scler; 2004 Jun; 10(3):281-3. PubMed ID: 15222692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Kostadinova II
    Arch Med Res; 2014 Aug; 45(6):495-500. PubMed ID: 25130430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-beta-1a treatment has a positive effect on quality of life of relapsing-remitting multiple sclerosis: results from a longitudinal study.
    Patti F; Pappalardo A; Montanari E; Pesci I; Barletta V; Pozzilli C
    J Neurol Sci; 2014 Feb; 337(1-2):180-5. PubMed ID: 24433926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered Immune Phenotypes and
    Devi-Marulkar P; Moraes-Cabe C; Campagne P; Corre B; Meghraoui-Kheddar A; Bondet V; Llibre A; Duffy D; Maillart E; Papeix C; Pellegrini S; Michel F
    Front Immunol; 2021; 12():628375. PubMed ID: 34113337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
    de Andrés C; Aristimuño C; de Las Heras V; Martínez-Ginés ML; Bartolomé M; Arroyo R; Navarro J; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
    J Neuroimmunol; 2007 Jan; 182(1-2):204-11. PubMed ID: 17157927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. History of modern multiple sclerosis therapy.
    Lublin F
    J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
    Durelli L; Barbero P; Bergui M; Versino E; Bassano MA; Verdun E; Ferrero B; Rivoiro C; Ferrero C; Picco E; Ripellino P; Viglietti D; Giuliani G; Montanari E; Clerico M;
    J Neurol; 2008 Sep; 255(9):1315-23. PubMed ID: 18825438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of interferon β-1a and interferon β-1b monotherapies on selected serum cytokines and nitrite levels in patients with relapsing-remitting multiple sclerosis: a 3-year longitudinal study.
    Stępień A; Chalimoniuk M; Lubina-Dąbrowska N; Chrapusta SJ; Galbo H; Langfort J
    Neuroimmunomodulation; 2013; 20(4):213-22. PubMed ID: 23711618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antinuclear antibodies and response to IFNbeta-1a therapy in relapsing-remitting multiple sclerosis.
    Ciccarelli O; Bagnato F; Mainero C; Salvetti M; Paolillo A; Gasperini C; Bastianello S; Pozzilli C
    Mult Scler; 2000 Jun; 6(3):137-9. PubMed ID: 10871823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.